<DOC>
	<DOCNO>NCT02895360</DOCNO>
	<brief_summary>Single-agent , open-label , multi-center sequential dose escalation expansion study BAL101553 , administer intravenous ( IV ) infusion 48 hour adult advance recurrent solid tumor .</brief_summary>
	<brief_title>Phase 1/2a Study BAL101553 Administered 48-hour Intravenous Infusions Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This first study prolong intravenous infusion BAL101553 . BAL101553 administer intravenous infusion 48 hour , adult advance recurrent solid tumor fail standard therapy , effective standard therapy available . The primary goal study find high dose BAL101553 safely give human assess side effect occur . The study start treat patient low dose . Once show low dose well tolerate , new patient treat high dose level ( `` dose escalation '' ) . Once high , well tolerate dose identify , 40 new patient treat dose ( part call `` dose expansion '' ) ass tolerability potential anticancer activity oral BAL101553 . The study also measure pharmacokinetics , pharmacodynamic effect assess biomarkers .</detailed_description>
	<criteria>1 . Age ≥ 18 year 2 . Patients either histologically cytologically confirm advanced recurrent solid tumor , fail standard therapy effective standard therapy available . 3 . Measurable tumor disease ( accord Response Evaluation Criteria Solid Tumors [ RECIST ] v1.1 ) 4 . Life expectancy ≥ 12 week 5 . Acceptable organ marrow function baseline ( protocol define laboratory parameter ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 7 . Other protocoldefined inclusion criterion may apply . 1 . Patients receive chemotherapy , radiotherapy , immunotherapy , investigational agent within 4 week prior start study drug recover side effect prior therapy 2 . Patients prior exposure BAL101553 . 3 . Inability swallow oral medication . 4 . Patients gastrointestinal disease . 5 . Patients malignant primary brain tumor . 6 . Symptomatic brain metastasis leptomeningeal disease , indicative active disease . 7 . Peripheral neuropathy ≥ CTCAE grade 2 . 8 . Uncontrolled intercurrent illness would unduly increase risk toxicity limit compliance study requirement 9 . Systolic blood pressure ( SBP ) ≥ 140 mmHg diastolic blood pressure ( DBP ) ≥ 90 mmHg screen visit . 10 . Blood pressure ( BP ) combination treatment two antihypertensive medication . 11 . Women pregnant breastfeeding . Men woman reproductive potential willing apply effective birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>